Zetagen Therapeutics Raises $12.9M in Oversubscribed Series B1 Round Following Promising Phase 2a Results for Breast Cancer Treatment
核心洞察
Zetagen Therapeutics (搜索) successfully closed a $12.9 million Series B1 financing round that was 100% oversubscribed, led by JSTAR Capital Investments (搜索).
The company's lead candidate ZetaMet demonstrated complete response in treated lesions and full bone regeneration in a Phase 2a trial for metastatic breast cancer (搜索) to bone.
Proceeds will advance ZetaMet toward commercialization and accelerate development of two additional intratumoral breast cancer therapies in the company's pipeline.
Zetagen Therapeutics (搜索), a clinical-stage biopharmaceutical company developing intratumoral treatments for breast cancer, announced the successful closure of its Series B1 financing round of $12.9 million. The round was 100% oversubscribed, reflecting strong investor confidence in the company's proprietary Zeta Platform and its potential to transform breast cancer care.
The funding round was led by JSTAR Capital Investments (搜索) and closed with strong demand from private investors, demonstrating deep confidence in the company's clinical efficacy data.
Strong Phase 2a Results Drive Investor Interest
"The strong demand in our Series B1 round highlights the promise of our Phase 2a clinical data for ZetaMet in treating metastatic breast cancer (搜索) to bone," said Joe C. Loy, CEO of Zetagen Therapeutics (搜索). "At the core of these encouraging results is our discovery of a novel molecular pathway—triggered by our compounds activating a conserved nuclear receptor (搜索)—which enables promising predictability in dosing and outcomes from bench to bedside."
The company's lead candidate, ZetaMet (Zeta-BC-003), completed a Phase 2a clinical trial at the University of British Columbia that demonstrated complete response in treated lesions, full bone regeneration, and no skeletal-related events. The treatment targets metastatic breast cancer (搜索) in bone through a single intratumoral injection, ceasing lytic activity, inhibiting pain, and regenerating new bone while minimizing skeletal related events such as fractures.
Comprehensive Pipeline Development
Proceeds from the Series B1 round will support the advancement of ZetaMet toward commercialization, accelerate clinical development of ZetaMast (搜索) (Zeta-MBC-005), and complete preclinical studies and GMP manufacturing of ZetaPrime (搜索) (Zeta-PBC-007).
ZetaMast for Liver Metastases
ZetaMast (搜索) is a novel hydrogel delivering two synergistic tumoricidal agents via a single intratumoral injection for breast cancer liver metastases (搜索) (BCLM). The treatment is designed to localize therapy and reduce systemic toxicity. Preclinical results published in PLOS ONE and co-authored by Dr. Debu Tripathy demonstrated reduced tumor burden, prevention of soft tissue metastases, and improved survival. A Phase 1b dose-escalation study is planned for the first half of 2026.
ZetaPrime for Primary Breast Cancer
ZetaPrime (搜索) is a neo-adjuvant treatment engineered for intratumoral administration following diagnosis. Utilizing a proprietary hydrogel-like lipid carrier, the formulation enables controlled release of two small molecules—one being a novel molecular entity and the ability to deliver a CDK4 (搜索) or CDK4/6 (搜索) protein inhibitor. The approach targets primary breast cancer (搜索) while aiming to mitigate off-target effects, potentially reducing the necessity for lumpectomies and mastectomies, decreasing radiation exposure, and enhancing patient survival.
In a single-dose in-vivo study, ZetaPrime (搜索) showed improved survival and tumor suppression compared to Tamoxifen and Verzenio in a mouse mammary fat pad model.
Strategic Milestones and Intellectual Property
The Series B1 funding follows several strategic milestones for Zetagen, including expansion of the company's global intellectual property portfolio to over 70 issued patents, including Composition-of-Matter patents and claims on ZetaMet, ZetaMast (搜索), and ZetaPrime (搜索). The company has also successfully completed the Phase 2a study of ZetaMet for metastatic breast cancer (搜索) to bone.
Upcoming Presentations
Zetagen will present preliminary clinical results for ZetaMet and in-vivo results for ZetaPrime (搜索), including head-to-head comparison data against Verzenio, at the upcoming San Antonio Breast Cancer Symposium (SABCS). The company will also attend the 2026 JP Morgan Healthcare Conference.
The entire Zeta Platform is designed for intratumoral administration to reduce off-target toxicity, utilizing proprietary carriers that incorporate the company's novel molecular entity. The USPTO has granted Zetagen Composition-of-Matter patents and claims for all three therapeutics in development.